Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.0 Contact Hour.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Sanofi Genzyme.

Community Practice Connections™: Exploring Novel Antibody-Based Treatments for Relapsed/Refractory Multiple Myeloma: How the Experts Think and Treat

Release Date: July 31, 2020
Expiration Date: July 31, 2021

Activity Overview

This online education activity is designed to provide expert commentary regarding recent clinical data on the efficacy and safety of monoclonal antibody therapy in patients with newly diagnosed multiple myeloma and with relapsed/refractory multiple myeloma. Advances in understanding the molecular mechanism of action of monoclonal antibody therapies in multiple myeloma (MM) and how this contributes to the development of prognostic and predictive biomarkers are also discussed. This activity is presented in a multimedia format that includes a series of video interviews with expert thought leaders integrated into text-based elements.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Sanofi Genzyme.

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.

Target Audience

This educational activity is directed toward medical oncologists and hematologists who treat patients with MM. Fellows, nurses, nurse practitioners, physician assistants, and other health care professionals interested in the management of patients with MM are also invited to participate.

Learning Objectives

Upon successful completion of this educational activity, you should be better prepared to:

  • differentiate the mechanism of action, safety, and efficacy profiles of established and novel monoclonal antibodies for the treatment of MM;
  • interpret the results of recent combination trials using monoclonal antibodies in relapsed/refractory MM and their applications to practice; and
  • understand how to best select therapies for relapsed/refractory MM based on patient risk stratification, prior therapeutic regimens, and other clinical considerations.

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER® has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Program Chair

Kenneth C. Anderson, MD
Kenneth C. Anderson, MD
Kraft Family Professor of Medicine
Harvard Medical School
Program Director, Jerome Lipper Multiple Myeloma Center and LeBow Institute for Myeloma Therapeutics
Institute Physician
Dana-Farber Cancer Institute
Boston, MA

Disclosures: Consultant: Bristol Myers Squibb Company, Celgene Corporation, Gilead Sciences Inc, Janssen Pharmaceuticals Inc, Millennium Pharmaceuticals Inc, Precision BioSciences Inc, Sanofi-Aventis US LLC, Tolero Pharmaceuticals Inc; Other: Scientific founder: C4 Therapeutics Inc, OncoPep Inc.


Meral Beksac, MD
Meral Beksac, MD
Professor of Hematology
Ankara University School of Medicine
Director, Ankara University Cord Blood Bank
Vice Chair, Plasma Cell Disorders Subcommittee
European Society for Blood and Marrow Transplantation
Vice President, Balkan Myeloma Study Group
Ankara, Turkey

Disclosures: Consultant: Amgen Inc, Celgene Corporation, Sanofi SA, Takeda Pharmaceutical Co Ltd; Speaker’s Bureau: Amgen Inc, Celgene Corporation, Sanofi SA, Takeda Pharmaceutical Co Ltd.

María-Victoria Mateos, MD, PhD
María-Victoria Mateos, MD, PhD
Associate Professor and Consultant Physician
Hematology Department
University Hospital of Salamanca
Salamanca, Spain

Disclosures: Consultant: Janssen Pharmaceuticals Inc, Celgene Corporation, Amgen Inc, Takeda Pharmaceutical Co Ltd, Adaptive Biotechnologies Corp, AbbVie Inc, GlaxoSmithKline plc, Pfizer Inc, Regeneron Pharmaceuticals Inc.

Enrique M. Ocio, MD, PhD
Enrique M. Ocio, MD, PhD
Head, Hematology Department
Marqués de Valdecilla University Hospital
University of Cantabria
Santander, Spain

Disclosures: Consultant: Amgen Inc, Celgene Corporation, Janssen Pharmaceuticals Inc, Oncopeptides AB, Sanofi SA, Secura Bio Inc; Other: Honoraria: Amgen Inc, Asofarma, Celgene Corporation, Janssen Pharmaceuticals Inc, Merck Sharp & Dohme Corp, Takeda Pharmaceutical Co Ltd.

The staff of Physicians' Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests to disclose.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By